Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Femrx(fmrx) -- Ignore unavailable to you. Want to Upgrade?

To: John T. Hardee who wrote (29)	11/22/1997 12:57:00 AM
From: Mayank Tandon	Read Replies (1) \| Respond to of 35

This thread has been very quiet of late. I bought into this company @ $ 3.25 after doing my due diligence and strongly believe that the LT prospects for FMRX are outstanding to say the least. Of course, how well the company is able to market its revolutionary technique will be key going forward. I am eagerly looking forward to the company's revenue growth performance in 4Q. This should provide us with an indication of how well its marketing efforts are shaping up. The fact that FMRX has $ 1.50+ per share in cash and virtually no LT debt should hold it in good stead during its development stage. Also, this leads me to believe that there is little chance of dilution in the near future. Anyone have any information as to who are the institutions invested in this company and the magnitude of insider holdings.